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Abstract: Although the prevalence of pulmonary hypertension (PH) in individuals with chronic 
obstructive pulmonary disease (COPD) is not known precisely, approximately 10%–30% of 
patients with moderate to severe COPD have elevated pulmonary pressures. The vast majority 
of PH associated with COPD is mild to moderate and severe PH occurs in  5% of patients. 
When COPD is associated with PH, both mortality and morbidity are increased. There are no 
clinical or physical examination ﬁ  ndings that accurately identify patients with underlying PH. 
Radiographic imaging ﬁ  ndings are speciﬁ  c but not sensitive indicators of PH. Echocardiography 
is the principle noninvasive diagnostic test but may be technically limited in a signiﬁ  cant propor-
tion of patients with COPD. Right heart catheterization is required for accurate measurement of 
pulmonary pressures. The combined effects of inﬂ  ammation, endothelial cell dysfunction, and 
angiogenesis appear to contribute to the development of PH associated with COPD. Systemic 
vasodilators have not been found to be effective therapy. Selective pulmonary vasodilators 
including inhaled nitric oxide and phosphodiesterase inhibitors are promising treatments for 
patients with COPD associated PH but further evaluation of these medications is needed prior 
to their routine use.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a signiﬁ  cant health care burden 
worldwide and is the only major cause of death in the United States for which both 
mortality and morbidity are increasing (Murray and Lopez 1997; Hurd 2000). This 
disease process is manifest by progressive airﬂ  ow limitation, hyperinﬂ  ation and air 
trapping, hypoxemia, hypercapnea, and elevations in pulmonary vascular pressures. 
Clinically, individuals with COPD develop breathlessness, cough, sputum produc-
tion and disease exacerbations that impair quality of life. Factors that portend a poor 
prognosis include severity of airﬂ  ow limitation, ventilatory capacity, hypercapnea, 
and pulmonary hypertension (Burrows and Earle 1969; Weitzenblum et al 1981; 
Anthonisen et al 1986). Survival correlates negatively with pulmonary arterial pressure 
and pulmonary vascular resistance and patients with COPD and PH have increased 
morbidity and risk for hospitalizations for acute COPD exacerbations (Burrows et al 
1972; Weitzenblum et al 1984; Kessler et al 1999; Barbera et al 2003).
PH associated with COPD is increasingly recognized as a contributing factor to the 
clinical manifestations, morbidity, and mortality of the COPD disease process. This 
recognition has stimulated further research into the cellular and molecular processes 
contributing to the pathogenesis of PH associated with COPD and the development 
and testing of new therapeutic interventions. This review will examine the epidemiol-
ogy of PH associated with COPD, its clinical manifestations, methods of diagnosis, 
pathophysiology, and treatment strategies.
Prevalence
The prevalence of pulmonary hypertension (PH) in COPD has not been accurately 
measured in large epidemiologic studies because of the risks and expense of invasive International Journal of COPD 2008:3(1) 56
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pressure measurement by right heart catheterization. Most 
studies have utilized noninvasive measures to estimate pul-
monary arterial pressures. Estimates of the prevalence of PH 
in COPD are also confounded by patient selection. Studied 
patients have varying severity of obstructive lung disease as 
well as different levels of oxygenation. Finally, over the last 
several decades, different groups have used various minimal 
pressures to deﬁ  ne PH and severe PH (Table 1). Therefore, 
estimates of the prevalence of PH in patients with COPD 
vary widely based upon the deﬁ  nition of PH, the methods 
used to determine pulmonary pressures, and the physiologic 
characteristics of the studied population.
Earlier autopsy studies demonstrated anatomic evidence 
of right ventricular hypertrophy in patients with COPD. 
Two-thirds of patients with chronic bronchitis had evidence 
of right ventricular hypertrophy demonstrated by increased 
weight of the right ventricle (Millard and Reid 1974). 
Similarly, 71% of 20 patients dying of COPD had right 
ventricular hypertrophy (Scott 1976). In contrast, one-third 
of 104 patients with emphysema had autopsy evidence of 
right ventricular hypertrophy (Leopold and Gough 1957). 
Subsequent studies have suggested a correlation between 
right ventricular hypertrophy and hypoxemia in patients with 
COPD (Calverley et al 1992). Recent studies utilizing mag-
netic resonance imaging (MRI) to measure right ventricular 
wall thickness and volume non-invasively demonstrated 
a signiﬁ  cant increase in right ventricular wall mass that 
was classiﬁ  ed as concentric hypertrophy in patients with 
severe COPD and either normoxemia or mild hypoxemia 
(Vonk-Noordegraaf et al 2005).
Several studies have determined pulmonary pressures by 
right heart catheterization in groups of COPD patients with 
varying levels of physiologic impairment. In a series of 175 
patients with moderate to severe COPD (FEV1% = 40.2 ± 
11.1%) and mild hypoxemia (40.6% with PaO2  60 mmHg), 
62 (35%) had pulmonary artery pressures  20 mmHg at right 
heart catheterization (Weitzenblum et al 1981). The mean 
pulmonary artery pressure (mPAP) in the entire cohort was 
19.8 ± 7.6. Similar results were found in a study of 53 patients 
with severe COPD (FEV1%, 39.8 ± 16.2); the mPAP was 19.0 
± 4.3 and 23 (43%) had PH (mPAP  20 mmHg) (Doi et al 
2003). Seventeen of twenty-seven (63%) patients with mild 
to moderate hypoxemia had PH. The mPAP was slightly 
greater, 26.9 ± 8.9 mmHg, in 215 patients with severe COPD 
(FEV1%, 24.3%) who underwent right heart catheterization 
prior to lung volume reduction surgery or lung transplantation 
(Thabut et al 2005). Approximately half of these patients had 
PH (mPAP  25 mmHg) (Thabut et al 2005).
In a series of 120 patients with severe emphysema 
(FEV1%, 27% and PaO2, 65.9 ± 10.0 mmHg) who underwent 
right heart catheterization during evaluation for lung volume 
reduction surgery in the National Emphysema Treatment 
trial, Scharf and colleagues (Scharf et al 2002) found a mPAP 
of 26.3 ± 5.2 mmHg. Over 90% of these patients had PH, 
(mPAP  20 mmHg). Although PaO2 correlated inversely 
with mPAP, PaO2 was not an independent predictor of mPAP 
based upon multiple stepwise regression analysis (Scharf 
et al 2002). Severe PH, (mPAP  35 mmHg) occurred in 
6 patients, 5%. Thabet and colleagues (Thabut et al 2005) 
found severe PH (mPAP  45 mmHg) in 8 of 215 patients 
(3.7%) evaluated for lung volume reduction surgery or 
lung transplant, whereas, (in a retrospective review) only 
11 (1.1%) of 998 patients with COPD had this level of PH 
(Chaouat et al 2005). Thus, although the measured prevalence 
of PH in patients with COPD ranges from approximately 20 
to 50%, very few individuals have severe PH.
Measurements of pulmonary hemodynamics in patients 
with COPD have shown that pulmonary pressures increase 
significantly with exercise. Right heart catheterizations 
performed in 151 patients with COPD (FEV1%, 38 ± 12% 
and PaO2 72 ± 11 mmHg) by Oswald-Mammosser and col-
leagues (Oswald-Mammosser et al 1991) demonstrated PH 
(mPAP  20 mmHg) in 31 individuals, 21%. The mPAP at 
rest was signiﬁ  cantly greater, 19 ± 4.7 mmHg, in patients with 
hypoxemia (PaO2  60 mmHg) than in normoxemic patients, 
16.8 ± 4.9, p   0.05. Further, with exercise up to 40 watts, 
Table 1 Varying thresholds deﬁ  ning pulmonary hypertension and 
severe pulmonary hypertension
Study   Pulmonary  Severe pulmonary
 hypertension    hypertension 
 (mmHg)  (mmHg)
Weitzenblum et al 1981  mPAP  20 
Oswald-Mammosser   mPAP  20
et al 1991
Van Dijk, 1996 (149)  mPAP  20 and/or
 PA  systolic   30 
Pilates et al 2000  mPAP  25 
Kessler et al 2001  mPAP  20 
Arcasoy et al 2003  PA systolic  45 
Doi et al 2003  mPAP  20 
Scharf et al 2002  mPAP  20 or  mPAP  30 or
 PA  systolic   30 PA  systolic   45
Thabet et al 2005  mPAP  25 mPAP   45 
Stevens et al 2000    mPAP  40
Chaouat et al 2005    mPAP  40
Abbreviations: mPAP, mean pulmonary artery pressure; PA, systolic 
pulmonary artery systolic pressure.International Journal of COPD 2008:3(1) 57
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two-thirds, 99 of 151 patients, developed mPAP  30 mmHg. 
In the 49 patients in whom pulmonary vascular resistance 
could be calculated at both rest and with exercise, pulmonary 
vascular resistance did not change signiﬁ  cantly with exercise. 
Christensen and co-workers (Christensen et al 2004) demon-
strated a similar incidence of exercise induced PH, 65% in 
a series of 17 patients with COPD (FEV1% 35 ± 10%, PaO2 
10.6 ± 1.1 kPa) who exercised at a work load of 25 watts. The 
mPAP was 19.9 ± 4.5 mmHg at rest and increased to 35.0 ± 
2.2 mmHg with exercise. Eleven patients, 65%, had mPAP 
greater than 30 mmHg with exercise. Fujimoto and collabora-
tors (Fujimoto et al 2002) studied pulmonary hemodynamics 
in 75 patients with mild hypoxemia (PaO2  60 mmHg) at rest 
and either mild (FEV1%  50%), moderate (FEV1%  50% 
or  35%), or severe COPD (FEV1%  35%) at rest and with 
exercise. At rest, mPAP’s were 21.5 ± 2.7, 20.0 ± 4.2, and 
21.7 ± 1.1 mmHg in the mild, moderate, and severe groups, 
and increased to 32.7 ± 3.2, 38.1 ± 2.1, and 44.4 ± 2.0 mmHg, 
respectively, with exercise. Thus, exercise potently elevates 
PA pressures in individuals with COPD.
Kessler and co-workers (Kessler et al 2001) studied the 
change in pulmonary hemodynamics with time in a group of 
131 patients with moderate COPD (FEV1%, 34.6 ± 15.7% and 
PaO2 67.0 ± 10.4 mmHg). Upon initial right heart catheteriza-
tion, no patient had a resting mPAP  20 mmHg. After a mean 
interval of 6.8 ± 2.9 years, 33 (25%) patients had developed PH 
(mPAP  20) with a range of 20–32.5 mmHg. The average rate 
of increase in pulmonary arterial pressure was 0.4 mmHg/year. 
Patients who developed resting PH had higher resting and 
exercise mPAP and lower resting and exercise PaO2.
Thus, although numerous studies have measured pulmo-
nary hemodynamics in patients with COPD, the prevalence 
of PH is not accurately known. Analysis of these studies is 
confounded by different sub-groups of individuals with vary-
ing severities of COPD and oxygenation and generally small 
numbers of patients. Nonetheless, the minimal prevalence of 
PH in patients with at least 1 hospitalization for COPD has been 
estimated to be 10%–30% (Naeije 2005) and is as high as 90% 
in patients undergoing evaluation for lung volume reduction 
surgery (Scharf et al 2002). Exercise induced PH may occur 
in two-thirds of patients with COPD even when pulmonary 
pressures are normal at rest (Oswald-Mammosser et al 1991; 
Christensen et al 2004).
Diagnostic testing
Physical examination
In a retrospective analysis of 27 patients with COPD and 
severe PH, Chaouat and colleagues (Chaouat et al 2005) 
identiﬁ  ed 16 individuals with other diseases or processes 
including appetite suppressant exposure, collagen vascular 
disease, portal hypertension, left ventricular disease, throm-
boembolic disease, restrictive lung disease, and sleep apnea 
syndrome that could cause or contribute to the development 
of PH. Therefore, a careful clinical history is required to iden-
tify or exclude recognized causes of PH in individuals with 
COPD. A thorough medication history including prior use of 
anorexigens or chemotherapeutic agents should be elicited. 
Potential exposures to hepatitis B and C and HIV need to be 
evaluated with serologies. A high prevalence of pulmonary 
embolism, 25%, has been detected by spiral computed tomog-
raphy in patients with unexplained exacerbations of COPD 
(Tillie-Leblond et al 2006). Therefore, a careful evaluation 
to exclude chronic thromboembolic PH is warranted in all 
individuals with COPD. Other pulmonary processes such as 
concurrent interstitial lung disease should be pursued. Cottin 
and co-workers (Cottin et al 2005) described 61 patients with 
both emphysema of the upper lung zones and diffuse paren-
chymal lung disease with ﬁ  brosis of the lower lung zones, of 
whom approximately 47% had PH. A careful history of skin, 
joint, and muscle symptoms should be obtained to exclude 
connective tissue disease. Smoking is not only a leading cause 
of COPD, it is also a signiﬁ  cant risk factor for the development 
of ischemic heart disease; therefore, a complete cardiac history 
and review of symptoms is also important in the evaluation 
of PH in patients with COPD. Both systolic and diastolic left 
ventricular function should be assessed.
The signs and symptoms of PH in patients with COPD are 
subtle and are often obscured by the clinical manifestations of the 
lung disease. Exertional breathlessness may be due to worsening 
airﬂ  ow limitation and air trapping or to the development of PH 
(Salvaterra and Rubin 1993). Although the predictive value of 
speciﬁ  c symptoms and physical examination ﬁ  ndings in detect-
ing pulmonary vascular disease in a patient with COPD is not 
known, several signs and symptoms suggests the presence of 
PH (Salvaterra and Rubin 1993). Decreasing functional capac-
ity with stable pulmonary function testing suggests pulmonary 
vascular involvement. Signs of right ventricle enlargement 
or overload such as the presence of a right ventricular lift, 
prominent P2, right sided S4 gallop, and the murmur of tricuspid 
regurgitation suggest the presence of PH (Salvaterra and Rubin 
1993). Elevated jugular venous pressure, hepatojugular reﬂ  ux, 
and a pulsatile liver are often signs of tricuspid insufﬁ  ciency.
Chest imaging
The characteristic chest radiographic ﬁ  ndings of PH are 
enlargement of the central pulmonary arteries causing hilar International Journal of COPD 2008:3(1) 58
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prominence and rapid tapering of the arteries in the lung 
periphery. Co-existing emphysematous changes accentuate 
oligemia within the lung parenchyma. The hilar thoracic 
index, the ratio of the distance between the start of the 
divisions of the right and left pulmonary arteries and the 
transverse diameter of the chest, has been used to quantify 
widening of the mediastinum (Chetty et al 1982). PH is 
suggested by a hilar-thoracic index  0.36. Widening of the 
descending right pulmonary artery to  16 mm or the left 
descending pulmonary artery to  18 mm suggest PH in 
patients with COPD (Matthay et al 1981). Chhabra and De 
(Chhabra and De 2004 ) conﬁ  rmed the high sensitivity and 
positive predictive value, 100%, of the ﬁ  ndings of increased 
hilar-thoracic index and width of the descending branch of 
the right pulmonary artery ( 20 mm) in 50 patients with 
COPD but showed that both measures were insensitive and 
had a low negative predictive value.
Measurement of pulmonary vessels by chest CT imag-
ing has also been used to detect the presence of pulmonary 
hypertension. In a study of 36 patients with PH due to variable 
causes (4 had COPD), enlargement of the main pulmonary 
artery diameter to  29 mm had a sensitivity of 87%, a 
speciﬁ  city of 89%, and a positive predictive value of 97% 
(Tan et al 1998). Additionally, the presence of pulmonary 
hypertension was predicted if the ratio of the diameters of the 
segmental artery to the corresponding bronchus was  1 in 
3 or more lobes (Tan et al 1998). Other investigators have 
suggested that because the diameter of the main pulmonary 
artery varies normally, an absolute size threshold is not 
useful for the diagnosis of PH (Haimovici et al 1997). Ng 
and co-workers (Ng et al 1999) determined the ratio of the 
diameter of the main pulmonary artery to the diameter of 
the ascending aorta in a group of 50 patients with various 
pulmonary and cardiovascular diseases who had undergone 
right heart catheterization. A ratio of the pulmonary artery to 
aortic diameter  1 was 70% sensitive and 92% speciﬁ  c for 
PH. The positive predictive value was 96% and the negative 
predictive value was 52%. Thus, the presence of an enlarged 
main pulmonary artery with a diameter greater than that of 
the ascending aorta strongly suggests the presence of PH but 
a ratio  1 does not exclude the presence of PH.
Electrocardiogram
PH associated with COPD may cause right ventricular hyper-
trophy or strain. The electrocardiographic manifestations of 
cor pulmonale are relatively speciﬁ  c, 86%, but not sensitive, 
51%, for PH and do not correlate with the severity of PH 
(Oswald-Mammosser et al 1987; Himelman et al 1988).
Features of the electrocardiogram in patients with COPD 
that suggest PH include: A) P pulmonale, P-wave ampli-
tude  2.5 mm in leads II, III, and/or aVF; B) S1, S2, S3 
pattern; C) a S1, Q3 pattern; D) incomplete or complete 
right bundle branch block; E) evidence of RVH, R axis 
deviation  100°, dominant R wave in lead V1  7 mm in 
amplitude, ST segment depression and T wave inversion 
in leads V1 to V4, and deep S waves in leads V5, V6, I and 
aVL with a QRS duration  0.12 s; and F) low voltage QRS 
(Harrigan and Jones 2002; Barbera et al 2003).
Echocardiography
Noninvasive estimation of systolic pressures by Doppler 
echocardiography has been studied extensively for the detec-
tion of PH in individuals with COPD. Several techniques 
are used, but most frequently, tricuspid regurgitant ﬂ  ow 
is detected and the maximum jet velocity is measured by 
continuous wave Doppler. Using the Bernoulli principle, 
the peak velocity, v, is used to calculate the trans-tricuspid 
gradient, 4v2. The systolic PAP is considered equal to the 
RV systolic pressure as long as there is no evidence of RV 
outﬂ  ow obstruction. RV systolic pressure is calculated as 
the sum of the trans-tricuspid gradient plus the estimated 
right atrial pressure (RAP). Early studies used a ﬁ  xed esti-
mation of 15 mmHg for RAP whereas subsequent studies 
estimate the RAP based upon the size of the inferior vena 
cava during inspiration: no collapse, 15 mmHg; partial col-
lapse 10 mmHg; and complete collapse 5 mmHg (Bredikis 
and Liebson 1998; Arcasoy et al 2003). In addition to these 
estimations, determination of sPAP by Doppler echocardiog-
raphy is limited by technical factors. Tricuspid insufﬁ  ciency 
must be present to measure a maximal jet velocity. Chest wall 
conﬁ  guration, especially the presence of air trapping and 
cardiac orientation, may affect the utility of this technique 
in patients with COPD (Arcasoy et al 2003).
Doppler echocardiographic success in estimating sPAP 
in patients with COPD ranges from 26%–66% (Laaban et al 
1989; Tramarin et al 1991; Bach et al 1998; Arcasoy et al 
2003). In a series of 374 patients undergoing evaluation for 
lung transplantation, Arcasoy and colleagues (Arcasoy et al 
2003) were technically able to estimate sPAP in only 38% of 
patients with obstructive lung disease but were successful in 
54% of patients with interstitial lung disease and 67% with 
pulmonary vascular disease. A residual volume  150% 
of predicted reduced the success rate of Doppler echocar-
diography. In an unselected series of 73% patients with 
COPD seen in an outpatient clinic, sPAP could be estimated 
in 56, 77% (Higham et al 2001). Although there were no International Journal of COPD 2008:3(1) 59
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differences in spirometry and diffusing capacity between 
the measurable and non-measurable groups, lung volumes 
were not determined.
Laaban and colleagues (Laaban et al 1989) compared 
the measurement of PAP by Doppler echocardiography with 
right heart catheterization in 41 patients with stable COPD. 
The directly measured mean sPAP was 38.5 ± 14.9 mmHg 
and 21, 51%, had pressures  35mmHg. sPAP could be 
estimated by Doppler echocardiography in 27 patients, 66%, 
and correlated signiﬁ  cantly with the direct hemodynamic 
measurements, r = 0.65, p   0.001. In a select subgroup of 
patients who were undergoing evaluation for lung volume 
reduction surgery and had both Doppler echocardiography 
and right heart catheterization, Bach and co-workers (Bach 
et al 1998) did not ﬁ  nd a signiﬁ  cant correlation between 
the actual and estimated sPAP but suggested that this 
difference was due to a single outlying patient. A strong 
correlation between right heart catheterization and Doppler 
echocardiographic measurement of sPAP, r = 0.8, was seen 
a group of 106 patients undergoing evaluation prior to lung 
transplantation, of whom 45, 42.5%, had obstructive lung 
disease (Ben-Dor et al 2006).
Transcutaneous jugular venous Doppler echo is another 
sonographic technique to estimate pulmonary pressures 
(Matsuyama et al 2001). During a breath hold at the end 
of expiration, jugular venous ﬂ  ow velocities are measured 
by Doppler echo during diastole and systole. An increasing 
diastolic to systolic ﬂ  ow ratio correlates signiﬁ  cantly with 
mPAP measured during RHC (Matsuyama et al 2001). 
Using a diastolic to systolic ﬂ  ow velocity ratio of 1.0, the 
sensitivity of this technique was 71.4% and the speciﬁ  city 
was 95.3%. Limitations of transcutaneous jugular venous 
Doppler echo include variable ratios in patients with mild 
PH (25–35 mmHg) and variable ﬂ  ow rates with tachycardias 
and dysrhythmias.
Histopathology
In 1965, Hicken et al (1965) described the histopathologic 
changes in the pulmonary vasculature of patients with chronic 
bronchitis or emphysema and evidence of right ventricular 
hypertrophy. They noted a circular layer of smooth muscle in 
the media of the pulmonary arterioles that was not present in 
the smaller pulmonary arteries. Both the pulmonary arterioles 
and small pulmonary arteries had a layer of longitudinal 
smooth muscle beneath the internal elastic lamina but neither 
one of the vessels had signiﬁ  cant intimal ﬁ  brosis. Because 
these vascular changes were similar to the alterations reported 
in PH associated with high altitude, Hicken et al (1965) 
hypothesized that PH associated with hypoxic lung diseases 
such as COPD was caused solely by hypoxic vasoconstriction 
and arteriolar muscular hyperplasia. Subsequent observations 
that high altitude PH resolves after descent to lower altitudes 
(Grover et al 1996) suggested that PH associated with COPD 
might reverse with correction of hypoxemia. Contrary to the 
expected result, pulmonary pressures decreased but did not 
normalize in individuals with PH associated with COPD who 
were treated with supplemental oxygen therapy (Abraham 
et al 1968). Subsequent studies of acute and chronic oxygen 
therapy in patients with COPD also failed to show resolu-
tion of PH (Lejeune et al 1984; Timms et al 1985). These 
physiologic ﬁ  ndings suggested that the PH associated with 
COPD that persists after correction of hypoxemia is due to 
ﬁ  xed vascular remodeling and spurred further, more detailed 
histopathological studies (Wilkinson et al 1988; Peinado 
et al 1999; Hale et al 1980). In 1988, Wilkinson (Wilkinson 
et al 1988) observed similar histopathologic ﬁ  ndings in lung 
tissue from 10 patients with hypoxic cor pulmonale and 
COPD regardless of treatment with supplemental oxygen. 
The media of the muscular pulmonary arteries was normal 
or atrophic but the intima revealed an active deposition of 
longitudinal muscle, ﬁ  brosis and elastosis. The media of the 
normally poorly muscularized arterioles revealed a circular 
muscular coat bounded by a new internal elastic lamina. 
Luminal narrowing was present with frequent recanalization 
of the arteriolar lumen (Wilkinson et al 1988). Subsequent 
studies of lung tissue from individuals with moderate to 
severe COPD have consistently reported similar ﬁ  ndings 
(Wright et al 1983; Hale et al 1984; Wright et al 1992). 
Interestingly, when lung sections from smokers with COPD 
were compared with non-smokers, the density of the fully 
muscularized (0–300 µm diameter) pulmonary arteries and 
the thickness of the medial muscle layer was doubled and 
the depth of intimal ﬁ  brosis was tripled (Hale et al 1984). 
This intimal thickening is due to both smooth muscle cell 
proliferation and increased elastin and collagen deposition 
(Santos et al 2002).
Importantly, similar ﬁ  ndings of vascular remodeling are 
present in the pulmonary vasculature of smokers (Santos 
et al 2002; Hale et al 1980) and patients with mild COPD 
(Santos et al 2002). The earliest vascular changes are intimal 
thickening, luminal narrowing, and arteriolar muscularization 
(Hale et al 1980; Magee et al 1988; Barbera et al 1994; 
Peinado et al 1998). The degree of intimal thickening 
correlates with the severity of small airways disease and 
emphysema (Hale et al 1980). These very early histopatho-
logic ﬁ  ndings suggest that the morphologic changes in the International Journal of COPD 2008:3(1) 60
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pulmonary arteries are initiated by the toxic effects of tobacco 
smoke and progress in parallel with the parenchymal changes 
of COPD (Hale et al 1980) (Figure 1).
Pathophysiology
The pulmonary vasculature of patients with COPD associated 
PH is markedly abnormal and shows increased intimal and 
medial thickening that cause luminal narrowing and vascular 
obstruction of the small pulmonary arteries (Wright et al 1992). 
These vascular changes lead to an increase in pulmonary 
vascular resistance (PVR) and elevation of pulmonary artery 
pressures (PAP). The severity of vascular abnormalities does 
not correlate directly with the pulmonary pressure at rest 
(Wilkinson et al 1988; Wright et al 1992). However, the degree 
of intimal thickening is proportional to the increase in pulmo-
nary pressure during exercise and this relationship is thought to 
be due in part to decreased distensability and recruitment within 
the abnormal pulmonary vasculature (Kubo et al 2000).
In most cases, PH associated with COPD develops 
slowly over time and the pressure increases approximately 
0.4 mmHg yearly (Kessler et al 2001). Moderately severe 
COPD is associated with PH in 10%–35% of patients (Scharf 
et al 2002; Eddahibi et al 2003). PH leads to pressure over-
load of the right ventricle (RV). RV muscular hypertrophy 
occurs in response to the increased pulmonary pressures 
(Dias et al 2002) and occurs in up to 40%–70% of patients 
with COPD at autopsy (11,62). Hypertrophy is followed by 
contractile dysfunction of the RV (Voelkel et al 2006). The 
contractile dysfunction leads to RV dilation, a decrease in 
cardiac output, and an increase in right sided ﬁ  lling pressures 
(Voelkel et al 2006). The dilation and pressure overload of 
the RV causes left ventricular (LV) diastolic dysfunction 
(Louie et al 1995). Eventually, the ability of the RV to com-
pensate is overwhelmed and RV failure ensues.
Pathogenesis
The pathogenesis of the vascular abnormalities associated 
with COPD have not been fully elucidated but appear to be 
caused by the combined effects of hypoxia (Burrows 1974), 
pulmonary dysfunction with air trapping (Wright 1993) and 
the toxic effects of smoking (Santos et al 2002; Hale et al 
1980) leading to inﬂ  ammation (Peinado et al 1999), endothe-
lial dysfunction (Dinh-Xuan et al 1991; Peinado et al 1998), 
and angiogenesis (Santos et al 2003) (Figure 2).
Hypoxia
Unlike the systemic circulation, acute hypoxia causes vasocon-
striction in the pulmonary circulation (Von Euler and Liljer-
starand 1946) and a transient increase in pulmonary vascular 
resistance (Pease et al 1982). Although the effect of recurrent, 
transient episodes of hypoxia in the development of pulmo-
nary vascular dysfunction is unclear, chronic hypoxia has 
been studied extensively and is a known cause of PH (Heath 
et al 1973; Thompson et al 1989; Vender 1994; Reeves and 
Grover 2005). The pathophysiologic mechanisms of hypoxic 
pulmonary vasoconstriction are not fully understood but are 
believed due to direct and indirect effects of lowered oxygen 
levels on the pulmonary vascular smooth muscle cells (Hida 
et al 2002). The direct action occurs through potassium and 
calcium channels (Weir and Archer 1995). In the presence of 
hypoxia, potassium channels within pulmonary smooth muscle 
cells close causing membrane depolarization and an inﬂ  ux of 
calcium, stimulating smooth muscle cell contraction (Weir 
and Archer 1995). Hypoxia may also act indirectly on the 
pulmonary vasculature by stimulating the production of tran-
scription factors (Yan et al 1998; Mechtcheriakova et al 1999) 
such as hypoxia-inducible factor-1 (HIF-1) (Semenza 2000; Yu 
et al 1998) and the release of multiple endogenous mediators 
including angiotensin II (Morrell et al 1995), endothelin-1 
(Chen et al 1995; DiCarlo et al 1995; Elton etal 1992; Hu 
et al 1998), and growth factors (Mechtcheriakova et al 1999; 
Santos et al 2003). These mediators trigger vasoconstriction, 
vascular remodeling, and angiogenesis.
Disturbances in pulmonary function/air 
trapping
Animal models of smoke-induced emphysema and PH sug-
gest that PH associated with COPD is due in some part to 
hyperinﬂ  ation and gas trapping that compress the pulmonary 
Figure 1 Histologic evidence of vascular changes in a small pulmonary artery in 
a patient with COPD and associated pulmonary hypertension. Hematoxylin and 
eosin staining demonstrates marked medial and intimal thickening with resulting 
luminal narrowing (40X, original magniﬁ  cation). Photomicrograph was provided 
courtesy of Hai Bui, MD, Department of Pathology, Cincinnati VAMC, Cincinnati Ohio.International Journal of COPD 2008:3(1) 61
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Figure 2 Pathophysiology of PH and right ventricular dysfunction associated with COPD. The combined action of hypoxemia, toxic tobacco smoke, pulmonary dysfunction, 
and polycythemia lead to endothelial dysfunction, growth factor production, and inﬂ  ammation in the pulmonary vasculature. These processes cause elevation of pulmonary 
arterial pressures. PH may cause RV hypertrophy and subsequent RV contractile dysfunction and RV failure.
vessels (Wright 1993). However, PH has not been shown to 
improve after lung volume reduction surgery (LVRS) despite 
improvement in pulmonary function and reduction in gas 
trapping (Haniuda et al 2003).
Polycythemia
Secondary polycythemia occurs in COPD with hypoxia and 
causes an increase in blood viscosity. However, to date, there 
are few studies evaluating the relationship between blood 
viscosity, polycythemia, and PH. A retrospective analysis of 
41 patients with emphysema revealed that increasing levels 
of hemoglobin independently correlated with increasing PVR 
and PAP (Nakamura et al 2000). Polycythemia also inhibits 
the vasodilatory effect of acetylcholine in patients with COPD. 
This effect is believed to be due to the inactivation of endothe-
lial derived NO by hemoglobin (Defouilloy et al 1998).
Toxic effects of cigarette smoke
Tobacco smoke is not only toxic to the airways and lung paren-
chyma but also has an effect on the pulmonary vasculature 
and may play a signiﬁ  cant role in the development of PH. The 
small pulmonary arteries of smokers develop intimal thicken-
ing due to elastin deposition, increased collagen production, 
and smooth muscle proliferation regardless of the develop-
ment of obstructive lung disease (Santos et al 2002; Hale et al 
1980). The etiology of these changes is not fully understood; 
however, tobacco smoke does induce vascular inﬂ  ammation 
(Peinado et al 1999) and impairs endothelial function (Barbera 
et al 2001). The number of CD8+ T-lymphocytes inﬁ  ltrating 
the adventitia of the small muscular pulmonary arteries is 
increased in both smokers and patients with COPD. The degree 
of inﬂ  ammatory inﬁ  ltrate correlates positively with pulmonary 
arterial intimal thickness in patients with COPD (Peinado et al 
1999). It is possible that this inﬂ  ammatory inﬁ  ltrate serves as 
a source of cytokines and growth factors leading to the medial 
hypertrophy, thickening, and luminal obstruction observed in 
smokers (Peinado et al 1999).
Vasoactive mediators also appear to play a role in smoking 
related pulmonary vascular changes. Brief exposure to tobacco 
smoke up-regulates gene expression of the vasoconstrictor/
vasoproliferative agents endothelin-1 (ET-1) and vascular 
endothelial growth factor (VEGF) in Sprague-Dawley rats 
(Wright et al 2002). The expression of VEGF is also increased 
in the pulmonary arteries of smokers and correlates with the 
thickness of the pulmonary arteries and the degree of obstruc-
tive lung disease (Santos et al 2003). Smoke exposure also 
alters NO production in endothelial cells. When the lungs of 
smokers are compared with those of non-smokers, smokers 
have lower endothelial nitric oxide synthase (eNOS) levels 
(Barbera et al 2001). Further, in vitro exposure of pulmonary International Journal of COPD 2008:3(1) 62
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artery endothelial cells to tobacco smoke causes irreversible 
inhibition of eNOS activity (Su et al 1998).
Genetics
Multiple genetic polymorphisms within several different 
genes correlate with the development of pulmonary vascular 
disease in patients with COPD associated PH. The angio-
tensin converting enzyme (ACE) gene contains insertion (I) 
or deletion (D) polymorphisms that create three genotypes 
(DD, II, and DI) (Rigatet al 1992). The deletion polymor-
phism is associated with increases in circulating angiotensin 
converting enzyme (ACE) levels (Rigat et al 1990). The DI 
polymorphism is associated with the development of PH 
in Caucasians with COPD (Tkacova et al 2005). Addition-
ally, the DI genotype may confer susceptibility to exercise 
induced PH in patients with COPD (Kanazawa et al 2000). 
Polymorphisms of the endothelial nitric oxide synthase 
(eNOS) gene are also present in patients with COPD. The 
BB polymorphism of the eNOS gene is associated with PH 
in patients with COPD. (Yildiz et al 2003). The serotonin 
transporter (5-HTT) plays a role in smooth muscle hyperpla-
sia and vascular remodeling (Eddahibi et al 2001). L allelic 
polymorphisms of the 5-HTT gene promoter cause 5-HTT 
over-expression. LL and LS 5-HTT are more common in 
patients with idiopathic pulmonary arterial hypertension 
(IPAH) than in controls (Eddahibi et al 2001). In patients 
with COPD, the LL 5-HTT gene polymorphism is associ-
ated with the presence of PH in hypoxemic COPD patients 
and correlates with the severity of PH (Eddahibi et al 2003). 
The GG polymorphism of the interleukin-6 (IL-6) gene leads 
to increased levels of IL-6 and occurs more commonly in 
COPD patients with PH than in those with COPD alone 
(Yildiz et al 2003).
Pathobiology
Endothelial dysfunction
The production of vasoactive chemokines by pulmonary 
endothelial cells is dysregulated during hypoxic stress (Chen 
et al 1995; DiCarlo et al 1995; Elton et al 1992) and toxin 
exposure (Wright et al 2002; Wright et al 2004; Santo et al 
2003). Endothelial dysfunction also occurs in patients with 
COPD (Dinh-Xuan et al 1991; Peinado et al 1999) and with 
COPD associated PH (Giaid et al 1993; Clini et al 2000).
Nitric oxide (NO) is a potent vasodilating mediator with 
antiproliferative effects (Murad 1997). NO is synthesized in 
the pulmonary vasculature by endothelial nitric oxide synthase 
(eNOS). eNOS expression is reduced in smokers (Barbera 
et al 2001) and patients with COPD (Giaid and Saleh 1995). 
Fractional exhaled nitric oxide (FENO) is also reduced in 
patients with COPD and PH. FENO levels correlate inversely 
with the degree of PH and the development of cor pulmonale 
(Clini et al 2000). It is postulated that the reduction in FENO 
seen in patients with COPD, PH, and cor pulmonale is due to 
a decrease in endothelial production of NO.
Prostacyclin is another potent endothelial cell-derived 
vasodilating mediator that inhibits platelet aggregation 
(Gerber et al 1980) and has antiproliferative effects (Hara 
et al 1995). It is synthesized by prostacyclin synthase via the 
arachidonic acid pathway (Alhenc-Gelas et al 1982). Pros-
tacyclin synthase is reduced in patients with IPAH (Tuder 
et al 1999) and in patients with emphysema (Lee et al 2005; 
Nana-Sinkam et al 2006). However, little is known about the 
role that prostacyclin plays in COPD associated PH.
Endothelin (ET-1) is a potent vasoconstricting 
(LeDouceur et al 1993) and mitogenic mediator produced 
by the endothelium (Dubin et al 1989; Boscoe et al 2000; 
Wedgewood et al 2001). Endothelin levels are increased 
in patients with COPD (Spiropoulos et al 2003), and rise 
further during COPD exacerbations (Roland et al 2001). 
Endothelin levels are increased in patients with pulmonary 
arterial hypertension (PAH) and PH associated with COPD, 
interstitial lung disease (ILD) and congestive heart failure 
(CHF) (Giaid et al 1993).
Growth factors
It is currently unclear what role growth factors play in the 
development and maintenance of the pulmonary vascular 
abnormalities observed in COPD and PH (Papaioannou et al 
2006). VEGF is an endothelial growth factor that stimulates 
angiogenesis and permeability (Papaioannou et al 2006). 
VEGF expression is increased in the pulmonary arteries 
of patients with COPD (Santos et al 2003). Hypoxia also 
stimulates VEGF production via the transcription factor 
Hypoxia-Inducible Factor-1 (HIF-1) (Carmeliet et al 1998; 
Iyer et al 1998; Semenza 2000). Although VEGF is a potent 
endothelial cell mitogen and is increased in smokers and 
patients with COPD and hypoxia, VEGF may also have a 
protective role in the pulmonary vasculature. When animals 
treated with a VEGF inhibitor are exposed to hypoxic con-
ditions, severe PH develops (Taraseviciene-Stewart et al 
2001). Additional studies are needed to understand VEGF’s 
potential protective role in the development of pulmonary 
vascular changes in patients with COPD.
Platelet derived growth factor (PDGF) is another mediator 
of angiogenesis that may be involved in vascular remodel-
ing in hypoxia and COPD. PDGF is a potent mitogen for International Journal of COPD 2008:3(1) 63
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smooth muscle cells (Hannink and Donoghue 1989). Indirect 
evidence that PDGF is important in the development of PH 
comes from rat models of hypoxic and monocrotaline induced 
PH that demonstrate reversal of PH after inhibition of PDGF 
(Schermuly et al 2005).
Inﬂ  ammation
The role of inﬂ  ammation in the pathogenesis of COPD 
associated PH is uncertain. The degree of inﬂ  ammatory inﬁ  l-
trate within the pulmonary vascular adventitia of patients with 
COPD correlates with the severity of the intimal thickening 
in the pulmonary arteries (Peinado et al 1999). Additionally, 
systemic inﬂ  ammatory markers, C-reactive protein (CRP), 
and tumor necrosis factor alpha (TNF-alpha), are increased 
in COPD patients with PH (Joppa et al 2006) when compared 
with COPD patients without PH. However, the signiﬁ  cance 
of these ﬁ  ndings is unclear and additional investigations 
are needed to determine the etiologic significance of 
inﬂ  ammation in the vascular remodeling that occurs with 
smoking, COPD, and COPD associated PH.
Management
The treatment of patients with COPD associated PH requires 
a multifaceted approach that includes smoking cessation, 
optimization of COPD management, and correction of 
hypoxemia. Additionally, recent advances in the understand-
ing of the pathogenesis of COPD associated PH provide 
several potential biologic targets for future therapies.
Smoking cessation
Toxic effects of tobacco smoke (Santos et al 2002; Hale et al 
1980) play a role in the development of the pulmonary vas-
cular disease that occurs in COPD associated PH. Smoking 
cessation is the single most important intervention to slow 
progression of COPD (Anthonisen et al 1994; Anthonisen 
et al 2002) and thus likely decreases the risk of developing 
COPD associated PH. Once an individual quits smoking, 
resumption of cigarettes should be continually discouraged 
as there is a steeper rate of decline in FEV1 in patients who 
restart smoking than in those who smoke without interruption 
(Sherrill et al 1996).
Supplemental oxygen
Correction of hypoxemia with supplemental oxygen is also 
recommended therapy for patients with COPD and PH. Long 
term oxygen therapy is recommended for patients with COPD 
whose resting PaO2 is  55 mmHg or is between 56 and 59 
mmHg during rest, sleep, or exertion and who have clinical 
evidence of cor pulmonale or polycythemia (Celli et al 2004). 
Long term oxygen therapy (LTOT) improves survival in 
hypoxic COPD patients and is associated with a mild improve-
ment in pulmonary hemodynamics (Medical Research 
Council Working Party 1981; Nocturnal Oxygen Therapy 
Group 1980). Additionally, supplemental oxygen during 
exercise decreases PAP (Burrows et al 1972; Fujimoto et al 
2002), increases exercise tolerance (Fujimoto et al 2002) and 
improves RV function (Olvey et al 1980). Pulmonary pres-
sures are known to increase with sleep in patients with COPD 
associated PH (Raeside et al 2002). Acutely, oxygen therapy 
abolishes this nocturnal rise in pulmonary pressures (Raeside 
et al 2002). Long term nocturnal oxygen decreases pulmonary 
pressures in patients with moderate to severe COPD, PH, and 
daytime PaO2  60 mmHg but who experience nocturnal 
desaturation (Fletcher et al 1992). A 3 year randomized trial 
involving 51 patients with moderate to severe COPD and 
PH demonstrated that patients with nocturnal desaturation 
treated with supplemental oxygen experienced a 3.7 mm 
Hg decrease in PAP whereas those patients with nocturnal 
desaturation who were treated with room air experienced 
a 3.9 mm Hg increase in PAP (Fletcher et al 1992). LTOT 
also ameliorates the progression of COPD associated PH. In 
1985, Weitzenblum and colleagues (Weitzenblum et al 1985) 
evaluated the progression of COPD associated PH before and 
after 2–4 years of LTOT. Prior to LTOT, the PAP increased 
by approximately 1.47 ± 2.3 mmHg per year whereas the 
PAP decreased by 2.15 ± 4.4 mmHg per year with oxygen 
therapy. Despite the beneﬁ  cial effects of oxygen therapy in 
patients with hypoxemia and COPD, LTOT does not lead 
to the normalization of pulmonary pressures (Abraham et al 
1968) or the reversal of morphologic derangements in the 
pulmonary vasculature (Wilkinson et al 1988). Therefore, 
additional interventions are needed to treat the ﬁ  xed vascular 
remodeling in COPD associated PH.
Systemic vasodilators
Calcium channel blockers (CCB) have been studied exten-
sively in COPD associated PH. Acutely, the administration of 
a short acting CCB (nifedipine) decreases the PAP, increases 
cardiac index (CI) (3.7 ± 0.2 to 4.6 ± 0.3 L/min/m2) and 
decreases PVR (426 ± 52 to 294 ± 28 dyne•s−1•cm−5) (Sturani 
et al 1983). The acute improvement in hemodynamics with 
CCB has been reproduced by several other investigators 
(Garzaniti et al 1985; Muramoto et al 1985). Despite the 
acute beneﬁ  cial effects of CCB’s, they are ineffective long 
term pulmonary vasodilators (Agostoni et al 1989) and do 
not effect progression of COPD associated PH (Sturani et al International Journal of COPD 2008:3(1) 64
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1983). Additionally, CCB’s can alter ventilation perfusion 
(VQ) matching deleteriously and worsen hypoxemia (Melot 
et al 1984). Due to these negative side effects, CCB’s are 
not recommended in the routine management of COPD 
associated PH.
Hydralazine has been tested in stable patients with PH 
secondary to COPD. Acutely, hydralazine improved pul-
monary hemodynamics and oxygenation in a small group 
of hypoxemic COPD patients (Keller et al 1984). However, 
nearly one quarter of the patients (3/14) could not tolerate 
hydralazine due to tachycardia. Hydralazine neither improves 
pulmonary hemodynamics in patients during COPD exacer-
bations nor increases exercise capacity in patients with severe 
COPD and associated PH (Cerda et al 1985; Dal Nogare 
and Rubin 1986).
Modulation of the renin-angiotensin systems has also 
been studied in COPD associated PH. Animal studies 
suggested that angiotensin converting enzyme (ACE) 
inhibition may be beneﬁ  cial in the treatment of COPD 
associated PH (Nong et al 1996); however the intravenous 
administration of captopril did not result in an acute change 
on pulmonary hemodynamics in patients with COPD 
(Patakas et al 1988). Furthermore, chronic treatment of 
patients with COPD associated PH with losartan did not 
result in a statistically signiﬁ  cant change in echocardiog-
raphy, exercise capacity, or respiratory symptoms (Morrell 
et al 2005).
Theophylline
Theophylline is a phosphodiesterase inhibitor used in the 
treatment of COPD. In a small study, it has been shown to 
reduce pulmonary artery pressures acutely with intravenous 
bolus administration (Liu et al 1992). Further studies are 
needed to validate this ﬁ  nding and to assess the effect of 
chronic theophylline therapy on COPD associated PH.
Future therapeutic targets
The most likely targets of future therapies in COPD associ-
ated PH are the endothelium and pulmonary vascular remod-
eling. Interventions aimed at these targets include nitric oxide 
(NO), phosphodiesterase inhibitors (PDEI) and statins.
NO is a selective pulmonary vasodilator that does not 
cause systemic hypotension (Pepke-Zaba et al 1991) and 
is effective treatment for idiopathic PH (Pepke-Zaba et al 
1991). In patients with COPD associated PH, 3 months of 
therapy with inhaled pulsed NO via nasal cannula improved 
pulmonary hemodynamics. The mean pulmonary artery 
pressure (mPAP) decreased from 27.6 to 20.6 mmHg, 
PVR decreased from 276.9 to 173 dyne•s−1•cm−5 and no 
worsening of hypoxemia occurred (Vonbank et al 2003). 
However, when Barbera and colleagues (Barbera et al 1996) 
administered inhaled NO (40 ppm) to patients with COPD, 
VQ matching worsened.
Phosphodiesterase inhibitors (PDEI) have been tested in 
small numbers of patients with COPD associated PH. PDEI 
prolong the effect of NO by inhibiting the degradation of 
NO’s second messenger (cGMP) and promoting smooth 
muscle relaxation (Rabe et al 1994). In 6 patients with COPD 
associated PH, pulmonary hemodynamics improved after 
the initial dose of intravenous sildenaﬁ  l and, after 3 months 
of oral therapy with sildenaﬁ  l 50mg twice daily, the mPAP 
decreased from 30.2 ± 5.5 to 24.6 ± 4.2 mmHg, PVR declined 
from 401 ± 108 to 264 ± 52 dyne•s−1•cm−5 and the six minute 
walk distance increased from 351 ± 49 to 433 ± 52 m (Alp 
et al 2006).
Despite these promising, preliminary results demonstrating 
beneﬁ  cial effects of NO and PDEI in COPD associated PH, 
larger studies are needed to determine their safety and efﬁ  -
cacy in COPD associated PH. Prostacyclin and endothelin 
antagonists are also potential targets for therapy; however, 
very limited information exists on the use of these agents in 
COPD associated PH.
3-hydroxy-3-methyl-glutaryl – coenzyme-A (HMG-
CoA) reductase inhibitors (statins) have anti-inﬂ  ammatory, 
antioxidant, and antithrombogenic effects, restore endothelial 
function (Bonetti et al 2003), and may ameliorate the deleteri-
ous effects of tobacco smoking on the lung parenchyma and 
vasculature (Lee et al 2005). In rats exposed to 16 weeks of 
tobacco smoke with or without concomitant statin treatment, 
parenchymal destruction, vascular changes, and inﬂ  ammation 
were attenuated by statin administration (Lee et al 2005). 
Further studies of statins are needed to determine if they 
promote vascular remodeling in COPD and PH.
Summary
Pulmonary hypertension is a common feature of advanced 
COPD and is estimated to affect  20% of patients with 
advanced COPD (Weitzenblum et al 1981; Scharf et al 
2002; Oswald-Mammosser et al 1991). The vast majority 
of PH associated with COPD is mild to moderate (mPAP 
20–35 mmHg). Severe PH (mPAP  40 mmHg) occurs in 
 5% of patients with COPD (Chaouat et al 2005). Severe PH 
in patients with COPD reduces median survival by approxi-
mately 40 months (Chaouat et al 2005). The pathogenesis of 
PH associated with COPD has not been clearly elucidated 
but is likely due to the combined effects of inﬂ  ammation International Journal of COPD 2008:3(1) 65
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Figure 3 A. Posterior-anterior chest X-ray and B. Lateral chest X-ray demonstrating enlarged pulmonary arteries and severe hyperinﬂ  ation. The metallic opaciﬁ  cation is a 
left nipple ring. C. Chest CT scan at the level of the pulmonary outﬂ  ow tract demonstrating a main pulmonary artery diameter greater than the adjacent aorta. D. Chest 
CT scan at the level of the lower lobes demonstrating segmental pulmonary arteries that are larger than the accompanying bronchi. E. Chest CT at the same level as 
Figure 3C using parenchymal windows to demonstrate severe emphysematous changes throughout the lung parenchyma.
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(Peinado et al 1999), endothelial cell dysfunction (Dinh-Xuan 
et al 1991; Peinado et al 1998), and angiogenesis (Santos et al 
2003) that lead to intimal thickening, luminal narrowing, 
and arteriolar muscularization (Barbera et al 1994; Peinado 
et al 1998; Magee et al 1988; Hale et al 1980). Long-term 
oxygen therapy is a proven therapy for COPD associated PH 
(Medical Research Council Working Party 1981; Nocturnal 
Oxygen Therapy Group 1980). Systemic vasodilators have 
not been found to be effective therapy in COPD related 
pulmonary hypertension (Sturani et al 1983). Selective pul-
monary vasodilators are currently being evaluated. Inhaled 
NO (Vonbank et al 2003) and PDEI (Alp et al 2006) are 
promising treatments for patients with COPD associated 
PH. However, further evaluation of the safety, efﬁ  cacy, and 
optimal dosing of these medications is needed prior to routine 
use of these therapies in the management of PH associated 
with COPD.
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Case study
This 54 year old man smoked up to 3 to 4 packs per day for the 
past 36 years and continues to smoke occasional cigarettes. 
He is breathless walking down the hallway and has dyspnea 
with most daily activities. He has no cough or sputum pro-
duction. His medications include: a long acting beta agonist, 
short acting beta agonist, short acting anticholinergic, and 
an inhaled corticosteroid. The alpha-1 antitrypsin level was 
218. Physical examination revealed a resting SaO2 of 85%. 
The chest was hyperresonant with markedly reduced breath 
sounds with a prolonged expiratory phase but no wheezes. 
The left ventricular impulse was subxiphoid and the sec-
ond heart sound was increased. There was no clubbing or 
peripheral edema.
Pulmonary function studies:
TLC 8.35  110%
FRC 6.48  177%
RV 4.41  190%
FEV1  1.34  32% (Prebronchodilator)  1.35  32% (Postbroncho-
dilator)
FVC  3.84  73% (Prebronchodilator)  4.62  88% (Postbroncho-
dilator)
DLCO 3.30  8.6%
Echocardiogram showed normal left ventricular size and 
function with a left ventricular ejection fraction of 50%. The 
left ventricular wall thickness was normal and there were no 
regional wall motion abnormalities. Systolic and diastolic 
ventricular septal ﬂ  attening was present suggesting right 
ventricular (RV) pressure overload. The RV was mildly 
dilated and systolic function was mildly to moderately 
reduced. The systolic pulmonary artery pressure was calcu-
lated to be 51–56 mmHg assuming a right atrial pressure of 
5–10 mmHg. Agitated saline contrast study did not reveal 
an intracardiac shunt (Figure 3). 
Assessment for coexisting etiologies of pulmonary hyper-
tension was performed. Connective tissue disease serolo-
gies and HIV testing were negative. Ventilation perfusion 
scanning was interpreted as low probability for pulmonary 
embolism. Arterial blood gas sampling conﬁ  rmed resting 
hypoxemia but did not show hypercarbia. Liver function 
testing was normal and there was no clinical evidence of 
hepatic dysfunction. 
Treatment with long acting beta agonist, short acting beta 
agonist, short acting anticholinergic, and an inhaled cortico-
steroid was continued. Supplemental oxygen was instituted 
for resting hypoxemia. Smoking cessation was strongly 
encouraged and interventions were successful.
The patient’s dyspnea improved with smoking cessation, 
supplemental oxygen and inhaled therapies for COPD. He 
completed pulmonary rehabilitation and is now enrolled in 
a pulmonary rehabilitation maintenance program.
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